Last updated: February 27, 2026
What is NDC 70700-0326?
NDC 70700-0326 corresponds to a specific pharmaceutical product. Based on available databases, NDC 70700-0326 is associated with Otezla (apremilast), a prescription medication used primarily to treat psoriatic arthritis, plaque psoriasis, and Behçet’s disease. Approved by the FDA in 2014, Otezla is marketed by Celgene, now part of Bristol-Myers Squibb.
Market Overview
Market Size and Adoption
Otezla faces competition in the immunomodulator segment, primarily from TNF inhibitors (e.g., Humira, Enbrel) and IL-17 inhibitors (e.g., Cosentyx). Despite competition, Otezla's oral administration offers convenience, which favors its adoption.
- Estimated global psoriasis market in 2022: $16 billion, with psoriatic arthritis (PsA) sales accounting for approximately $4 billion[1].
- Otezla's U.S. market share: Estimated at 8-10% of the total psoriasis and PsA segments.
- Prescriptions in 2022: Approx. 2 million nationally, considering a broader immunology market.
- Revenue estimates for 2022: $1.2 billion, with potential growth driven by expanding indications and geographic penetration.
Regulatory and Approval Status
- Approved in the U.S. and Europe.
- In Japan, approval granted in 2021.
- Clinical trials underway for indications in hidradenitis suppurativa and ulcerative colitis.
Market Drivers
- Increasing prevalence of psoriasis and psoriatic arthritis globally.
- Rising use of oral therapies over injectable biologics.
- Expanding approved indications.
- Greater physician and patient awareness.
Key Market Challenges
- Generic and biosimilar competition for biologics.
- Side effect profile requiring monitoring (e.g., weight loss, depression).
- Pricing pressures and payer negotiations.
Price Analysis and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately $4,838 per month, equating to roughly $58,000 annually per patient (2022 data)[2].
- Average wholesale price (AWP): Around $64,000 annually, depending on dosage and discounts.
- Payer discounts and patient assistance programs lower actual net prices.
Price Trends
- Historically, Otezla's list price increased around 3-4% annually from its launch in 2014 to 2020.
- Price stabilization observed post-2020 amid increased competition.
- Biosimilars and generics threaten to push prices downward, especially in the European Union, where biosimilars are more widely adopted.
Future Price Projections (2023-2027)
| Year |
Estimated Average Annual Cost |
Rationale |
| 2023 |
$60,000 |
Stabilization post-price increases, no new formulations. |
| 2024 |
$58,500 |
Slight discounting due to competitive biosimilars. |
| 2025 |
$57,000 |
Increased biosimilar penetration, generic market growth. |
| 2026 |
$55,000 |
Continued downward pressure, expansion of biosimilar options. |
| 2027 |
$53,000 |
Cost compression driven by payer negotiation and biosimilar market share. |
Pricing Assumptions
- Biosimilar market share reaches 15-20% in the U.S. by 2025.
- Payer discounting and manufacturer rebates reduce net prices by 10-15% annually.
- Price erosion accelerates with increased biosimilar accessibility and external market factors.
Competitive Landscape
| Product |
Type |
Approximate Market Share |
Key Features |
| Humira (adalimumab) |
Biosimilar biologic |
35-40% |
Injected; broad autoimmune indications |
| Cosentyx (secukinumab) |
Biologic |
15-20% |
Injectable; preferred for axial spondyloarthritis |
| Otezla (apremilast) |
Oral small molecule |
8-10% |
Oral administration, moderate efficacy, lower injection burden |
| Enbrel (etanercept) |
Biologic |
10-15% |
Injectable; longstanding biologic in market |
Strategic Outlook
- Biosimilar competition is likely to suppress Otezla pricing.
- Expansion into new indications could sustain revenue, but approval timelines are lengthy.
- Market share gains are constrained by biosimilars and existing biologics' entrenched position.
- Price reductions and rebate strategies will be necessary for continued competitiveness.
Key Takeaways
- Current U.S. list price for Otezla approximates $58,000 annually per patient, with net prices lower due to discounts.
- Market share is capped at around 8-10%, influenced by biosimilar competition.
- Future pricing will decline gradually through 2027, driven by biosimilars comprising an increasing share of the market.
- The overall psoriasis and psoriatic arthritis markets present growth opportunities, but price competition will compress margins.
- Strategies focusing on new indications, combo therapies, or geographic expansion may offset price erosion.
FAQs
1. What factors influence Otezla's pricing?
Market competition, biosimilar penetration, payer negotiations, and manufacturer rebates.
2. How will biosimilars impact Otezla’s revenue?
Biosimilars' entry will drive down prices and reduce market share, increasing price competition.
3. Are there upcoming patent expirations affecting pricing?
Major patent protections for Otezla extend until 2027 in the U.S., after which biosimilars are expected to gain market share.
4. What are the primary competitors to Otezla?
Biologic agents such as Humira, Cosentyx, and Enbrel, which are administered via injection.
5. How might expansion into new indications affect pricing and market size?
New indications could boost sales but require significant investment and lengthy approval processes; pricing will still face biosimilar competition.
Sources
- Grand View Research. (2022). Psoriasis Market Size, Share & Trends Analysis.
- GoodRx. (2022). Otezla (apremilast) pricing details.
- FDA. (2014). Approval of Otezla for Psoriasis.
- IQVIA. (2022). US Prescription Data.
- Bristol-Myers Squibb. (2022). Financial reports and market disclosures.
